Spectrus’ Post

We're excited to unveil IntegriGut Screen Efficacy, our latest screening service that employs patient-derived organoid monolayers for IBD drug discovery and development. Leveraging the power of human organoids, IntegriGut Screen Efficacy enables IBD researchers to rapidly and accurately assess the protective effects of potential drug candidates on epithelial barrier integrity, cytotoxicity, and cytokine release. The key features of our screen are: 🔬Patient-derived in vitro model: Represents human intestinal biology with unparalleled accuracy 🔬Rapid and versatile: Delivers results within 3 weeks, screening up to 10 compounds per run 🔬3 independent assessments: Evaluates barrier function, cytotoxicity, and cytokine release 🔬Well-charecterised IBD biobank: The screening set-up includes PDOs from our estbalished IBD patient-derived biobank Curious to know more? Click on the below for more details. #IBD #inflammation #guthealth #digestivedisease #inflammatoryboweldisease #organoids #patientinthelab #gutorganoid

Koeberl et al. report interim results from the first-in-human phase I/II trial evaluating the safety and efficacy of mRNA-3927, an investigational mRNA therapeutic for #Propionicacidaemia (PA). PA is a #rare, #autosomalrecessive #metabolicdisorder caused by pathogenic variants in the genes encoding the α and/or β subunits of propionyl-coenzyme A carboxylase (PCC), a component of the #mitochondrialpropionatepathway. The resulting deficiency in PCC leads to the accumulation of toxic metabolites, causing recurrent life-threatening metabolic decompensation events.

What if cytokine biomarker data in clinical trials could be delivered more accurately and more quickly? Analyte stability is one of the most important parts of bioanalytical testing in clinical trials. To this end, the FDA recommends testing analytes in whole blood as well as plasma or serum to understand the impact of sample processing on biomarker concentrations.   Unfortunately, many labs focus only on plasma or serum stability and so can miss a critical part of the innate immune biomarker response ……rapid production in blood cells.   For example, IL-6 can be released by blood cells even before sample processing, and this could result in artificially high values.   Find out more about how Kypha’s processes can enhance clinical trial biomarker workflow to ensure measurement of the most accurate immune biomarker data at https://lnkd.in/egPyFs_n   #complement #cytokines #clinicaltrials #biomarkers #immunebiomarkers #workflow #diagnostics #complementdiagnostics #cytokinediagnostics #immunemonitoring

Exciting developments in companiom diagnostics .

What if cytokine biomarker data in clinical trials could be delivered more accurately and more quickly? Analyte stability is one of the most important parts of bioanalytical testing in clinical trials. To this end, the FDA recommends testing analytes in whole blood as well as plasma or serum to understand the impact of sample processing on biomarker concentrations. Unfortunately, many labs focus only on plasma or serum stability and so can miss a critical part of the innate immune biomarker response ……rapid production in blood cells. For example, IL-6 can be released by blood cells even before sample processing, and this could result in artificially high values. Find out more about how Kypha’s processes can enhance clinical trial biomarker workflow to ensure measurement of the most accurate immune biomarker data at https://lnkd.in/e_FhrM-9 #complement #cytokines #clinicaltrials #biomarkers #immunebiomarkers #workflow #diagnostics #complementdiagnostics #cytokinediagnostics #immunemonitoring

#Target ActRII — Fat Loss and Muscle Gain Target  Last July, Eli Lilly acquired Versanis for $1.925 billion, and then a potential target for weight loss surfaced—ActRII. Muscle growth inhibitor (MSTN) is a skeletal muscle limiting protein (ActRII is the main receptor for MSTN), and some studies have shown that its higher activity can inhibit skeletal muscle growth. ActRII has potential in muscle diseases, metabolic diseases such as obesity and diabetes, and cancer. 💡 Genomeditech independently designed and developed a series of overexpression ActRII / functional cell lines and antibodies, which can fully satisfy the needs of drug development and help the clinical filing of drugs. 👉 Click the link to know products: https://lnkd.in/gA2ieymd https://lnkd.in/g728s2_u https://lnkd.in/gviFVZtc https://lnkd.in/gnanupu3 #ActRII #antibodydiscovery #antibodytherapeutics #celllinedevelopment #cancertreatment #antibodies #drugdiscovery 👉Click on the link to leave a message so that we can offer you more services! www.genomeditech.com Illustration：Signal transduction through activin receptors

Explore the future of RNA therapeutics with Dr. Jeff Coller of John Hopkins University in our latest webinar. Learn about a novel therapeutic technique that not only improves mRNA translation but also offers precise control over protein expression, enabling a wide range of clinical applications. Click below to watch on-demand https://lnkd.in/gH6zycsd #therapeutics #mRNA #webinar

A recent study published in #Nature reports on NG2 glia, prostaglandin E2 (PGE2) signaling, and prion diseases, and we are happy to see Gesynta Pharma cofounder Per-Johan Jakobsson among the authors. Inflammation is involved in the progression of prion disease, and the results of this study suggest a crucial role for #PGE2 and the potential for 𝗺𝗣𝗚𝗘𝗦-𝟭 inhibitors in protecting the brain. Gesynta Pharma is developing mPGES-1 inhibitors to treat inflammatory diseases, with the lead drug candidate #vipoglanstat targeting #endometriosis. Follow the link to the full article: https://lnkd.in/e8cEZRhv '𝘕𝘎2 𝘨𝘭𝘪𝘢 𝘱𝘳𝘰𝘵𝘦𝘤𝘵 𝘢𝘨𝘢𝘪𝘯𝘴𝘵 𝘱𝘳𝘪𝘰𝘯 𝘯𝘦𝘶𝘳𝘰𝘵𝘰𝘹𝘪𝘤𝘪𝘵𝘺 𝘣𝘺 𝘪𝘯𝘩𝘪𝘣𝘪𝘵𝘪𝘯𝘨 𝘮𝘪𝘤𝘳𝘰𝘨𝘭𝘪𝘢-𝘵𝘰-𝘯𝘦𝘶𝘳𝘰𝘯 𝘱𝘳𝘰𝘴𝘵𝘢𝘨𝘭𝘢𝘯𝘥𝘪𝘯 𝘌2 𝘴𝘪𝘨𝘯𝘢𝘭𝘪𝘯𝘨' – 𝘕𝘢𝘵𝘶𝘳𝘦 𝘕𝘦𝘶𝘳𝘰𝘴𝘤𝘪𝘦𝘯𝘤𝘦 𝘷𝘰𝘭𝘶𝘮𝘦 27, 𝘱𝘱 1534–1544 (2024) #PrionDisease #NatureNeuroscience #PGE2signaling #mPGES1 #prostaglandinE2

The September edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month includes a first-in-human, double-blind, randomized, and placebo-controlled study evaluating the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of single ascending intravenous (IV) and subcutaneous (SC) doses of DS-7011a in healthy subjects. 🔗https://ow.ly/tFp150Tw8WU

The FDA has approved Merck's sotatercept for pulmonary arterial hypertension. https://lnkd.in/deP2u4qe I wrote about this activin receptor IIA (TGF-β family member) & human immunoglobulin IgG1 Fc domain fusion protein at the end of 2022: "Studies of familial disease have found that over 70% of cases have mutations in the BMPR2 gene, which encodes the TGF-β (transforming growth factor-β) family member BMPR-II (bone morphogenetic protein type II receptor), or in genes encoding molecules in the BMPR-II signaling pathway. Mutations in the BMPR-II pathway are also seen in idiopathic cases, and patients with BMPR2 mutations have an earlier age of onset and a more severe course of the disease." https://lnkd.in/dfVSyuTW